CoChat

Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19.

Open access
Kory, Pierre, Meduri, Gianfranco Umberto, Varon, Joseph, Iglesias, Jose, Marik, Paul E. · 2021 · American Journal of Therapeutics

The DOI matches its Crossref record; 82 of the 86 references it cites were found in a registry or an index.

Abstract

Background: After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed therapeutic agents were used empirically and studied within clinical trials. Areas of Uncertainty: The majority of trialed agents have failed to provide reproducible, definitive proof of efficacy in reducing the mortality of COVID-19 with the exception of corticosteroids in moderate to severe disease. Recently, evidence has emerged that the oral antiparasitic agent ivermectin exhibits numerous antiviral and anti-inflammatory mechanisms with trial results reporting significant outcome benefits. Given some have not passed peer review, several expert groups including Unitaid/World Health Organization have undertaken a systematic global effort to contact all active trial investigators to rapidly gather the data needed to grade and perform meta-analyses. Data Sources: Data were sourced from published peer-reviewed studies, manuscripts posted to preprint servers, expert meta-analyses, and numerous epidemiological analyses of regions with ivermectin distribution campaigns. Therapeutic Advances: A large majority of randomized and observational controlled trials of ivermectin are reporting repeated, large magnitude improvements in clinical outcomes. Numerous prophylaxis trials demonstrate that regular ivermectin use leads to large reductions in transmission. Multiple, large “natural experiments” occurred in regions that initiated “ivermectin distribution” campaigns followed by tight, reproducible, temporally associated decreases in case counts and case fatality rates compared with nearby regions without such campaigns. Conclusions: Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mjt.0000000000001377

Cites

82 of 84 references verified2 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1. Meta-analysis of ivermectin prophylaxis trials in COVID-19. OBS, observational study; RCT, randomized controlled trial. Symbols: Squares: Indicate treatment effect of an individual study. Large diamond: Reflect summary of study design immediately above. Size of each symbol correlates with the size of the confidence interval around the point estimate of treatment effect with larger sizes indicating a more precise confidence interval.
FIGURE 1. Meta-analysis of ivermectin prophylaxis trials in COVID-19. OBS, observational study; RCT, randomized controlled trial. Symbols: Squares: Indicate treatment effect of an individual study. Large diamond: Reflect summary of study design immediately above. Size of each symbol correlates with the size of the confidence interval around the point estimate of treatment effect with larger sizes indicating a more precise confidence interval.CC BY-NC-ND · PubMed Central
FIGURE 2. Meta-analysis of the outcome of time to clinical recovery from controlled trials of ivermectin treatment in COVID-19. OBS, observational study; RCT, randomized controlled trial. Symbols: Squares: Indicate treatment effect of an individual study. Large diamond: Reflect summary of study design immediately above. Small diamond: Sum effect of all trial designs. Size of each symbol correlates with the size of the confidence interval around the point estimate of treatment effect with larger sizes indicating a more precise confidence interval.
FIGURE 2. Meta-analysis of the outcome of time to clinical recovery from controlled trials of ivermectin treatment in COVID-19. OBS, observational study; RCT, randomized controlled trial. Symbols: Squares: Indicate treatment effect of an individual study. Large diamond: Reflect summary of study design immediately above. Small diamond: Sum effect of all trial designs. Size of each symbol correlates with the size of the confidence interval around the point estimate of treatment effect with larger sizes indicating a more precise confidence interval.CC BY-NC-ND · PubMed Central
FIGURE 3. Meta-analysis of the outcome of mortality from controlled trials of ivermectin treatment in COVID-19. OBS, observational study; RCT, randomized controlled trial. Symbols: Squares: Indicate treatment effect of an individual study. Large diamond: Reflect summary of study design immediately above. Small diamond: Sum effect of all trial designs. Size of each symbol correlates with the size of the confidence interval around the point estimate of treatment effect with larger sizes indicating a more precise confidence interval.
FIGURE 3. Meta-analysis of the outcome of mortality from controlled trials of ivermectin treatment in COVID-19. OBS, observational study; RCT, randomized controlled trial. Symbols: Squares: Indicate treatment effect of an individual study. Large diamond: Reflect summary of study design immediately above. Small diamond: Sum effect of all trial designs. Size of each symbol correlates with the size of the confidence interval around the point estimate of treatment effect with larger sizes indicating a more precise confidence interval.CC BY-NC-ND · PubMed Central
FIGURE 4. Decrease in total case incidences and total deaths/population of COVID-19 in the over 60 population among 8 Peruvian states after deploying mass ivermectin distribution campaigns.
FIGURE 4. Decrease in total case incidences and total deaths/population of COVID-19 in the over 60 population among 8 Peruvian states after deploying mass ivermectin distribution campaigns.CC BY-NC-ND · PubMed Central
FIGURE 5. Daily total deaths, case fatalities, and case incidence for COVID-19 in populations of patients aged 60 and older for 8 states in Peru deploying early mass ivermectin treatments versus the state of Lima, including the capital city, where ivermectin treatment was applied months later.
FIGURE 5. Daily total deaths, case fatalities, and case incidence for COVID-19 in populations of patients aged 60 and older for 8 states in Peru deploying early mass ivermectin treatments versus the state of Lima, including the capital city, where ivermectin treatment was applied months later.CC BY-NC-ND · PubMed Central
FIGURE 6. Covid-19 case fatalities and total deaths with and without mass ivermectin in different states of Peru.
FIGURE 6. Covid-19 case fatalities and total deaths with and without mass ivermectin in different states of Peru.CC BY-NC-ND · PubMed Central
FIGURE 7. Paraguay – COVID-19 case counts and deaths in Alto Parana (bolded blue line) after ivermectin distribution began compared to other regions.
FIGURE 7. Paraguay – COVID-19 case counts and deaths in Alto Parana (bolded blue line) after ivermectin distribution began compared to other regions.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 84 references

Research works printed but not linked: 1

  1. Prophylaxis, 2020, Covid-19 in healthcare agents by intensive treatment with ivermectin and iota-carrageenan (Ivercar-Tuc), ClinicalTrials.gov, NCT04701710

Cited by

See all 219

Metadata

Authors
Kory, P., Meduri, G. U., Varon, J., Iglesias, J., & Marik, P. E.
Affiliations
  • Front-Line Covid-19 Critical Care Alliance, Madison, WI;
  • University of Tennessee Health Science Center (US)
  • University of Texas Health Science Center, Critical Care Service, Houston, TX;
  • Department of Medicine, Hackensack School of Medicine, Seton Hall, NJ; and
  • Eastern Virginia Medical School (US)
Corresponding author
Kory, Pierre
Venue
American Journal of Therapeutics
Published
2021-04-22
Volume
28
Issue
3
Pages
e299-e318
ISSN
1075-2765 (ISSN-L)
OpenAlex
W3158596488
Cited by
203
References
86
Citations by year
2026: 3 · 2025: 9 · 2024: 21 · 2023: 59 · 2022: 56 · 2021: 54
FWCI
5.56
Type
journal article
Language
en
Open access
Locations
  • American Journal of Therapeutics (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords
ivermectin, COVID-19 pandemic, drug repurposing, prophylaxis, antiviral therapy, mortality reduction, natural experiment, SARS-CoV-2 transmission, viral clearance
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Antiparasitic Agents, Humans, Ivermectin, Treatment Outcome, Disease Transmission, Infectious

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. https://app.cochat.ai/papers/10.1097/mjt.0000000000001377
The paper
Kory, P., Meduri, G. U., Varon, J., Iglesias, J., & Marik, P. E. (2021). Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0000000000001377

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.